Search results
Akero Therapeutics, Inc. (AKRO) Investors: June 25, 2024 Filing Deadline in Securities Class Action...
Morningstar· 2 days ago(“Akero”) (NASDAQ: AKRO). As a result of Akero’s materially misleading statements and omissions to the public, Akero’s investors have suffered significant losses.
Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence...
Benzinga· 6 days agoVirios Therapeutics, Inc. VIRI (the "Company" or "Virios Therapeutics"), a development-stage biotechnology company focused on advancing novel antiviral ...
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF...
WKRN Nashville· 5 days agoFood and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex' azeliragon, a well-tolerated once-a-day pill, for the treatment of pancreatic cancer. This ...
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in...
WTRF Wheeling· 4 days agoFood and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to larsucosterol for the treatment of patients with severe alcohol-associated hepatitis ...
Hologic recalls more than 53,000 radiographic markers linked to 71 injuries
MedTech Dive via Yahoo Finance· 2 days agoSome patients have needed additional treatment to remove the device. The FDA said there have been 71...
Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili™. Enters U.S....
WTRF Wheeling· 4 days agoFood and Drug Administration (US FDA) has approved the Company's first-to-file application for Yesafili™ (aflibercept-jbvf), an interchangeable* biosimilar aflibercept. YESAFILI ...
Elite Pharmaceuticals Receives FDA Approval for Generic Methotrexate
Digital Journal· 5 days ago...Corporation's ReElement Technologies Corporation Has Been Approved and Accepted as Member in Defense Industrial Base Consortium Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules NexgenRx Announces...
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing...
FOX 59 Indianapolis· 8 hours agoNovartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G...
Boston’s Rapport Therapeutics lays out plans for IPO - Boston Business Journal
The Business Journals· 5 days agoJust a year after emerging from stealth, a Boston startup working on precision medicines for brain...
CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update
Digital Journal· 2 days agoOrganizational redesign on track, trimming residual pandemic infrastructure and reducing 150 positions by year endU.S. FDA Fast Track designation granted for pre-pandemic ...
